ReviewPediatric nephrology (Berlin, Germany)2012
Glucocorticoid-induced hypertension.
Review in Pediatric nephrology (Berlin, Germany), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 150 citations in OpenAlex.
- Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial.The European respiratory journal · 2020Trial
- Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis.Rheumatology (Oxford, England) · 2019Trial
- Argininosuccinate Lyase Deficiency Causes an Endothelial-Dependent Form of Hypertension.American journal of human genetics · 2018Trial
- Voluntary liquorice ingestion increases blood pressure via increased volume load, elevated peripheral arterial resistance, and decreased aortic compliance.Scientific reports · 2017Trial
- Hypertension in autoimmune rheumatic diseases: progress made, gaps remain.Journal of hypertension · 2026Article
- Benefits and risks of prophylactic glucocorticoids in platinum chemotherapy for extensive-stage small-cell lung cancer: A retrospective study.Molecular and clinical oncology · 2026Article
- Childhood systemic glucocorticoid exposure and subsequent alterations in myocardial structure and cardiac function: a narrative review of clinical evidence.Frontiers in endocrinology · 2026Review
- Revolutionizing rheumatoid arthritis therapy: the potential of lipid nanocarriers.RSC advances · 2025Review
- Navigating the Complexities of Cancer Treatment-Induced Hypertension.Journal of cardiovascular development and disease · 2025Review
- Urinary Proteome Characterization of Stroke-Prone Spontaneously Hypertensive Rats.International journal of molecular sciences · 2024Article
- Article
- Glucocorticoid excess alters metabolic rate and substrate utilisation via 11β-HSD1.The Journal of endocrinology · 2024Article
- No Muscle Left Behind: Cardiac Arrest and Myocarditis in a Patient With Idiopathic Inflammatory Myopathy.Cureus · 2024Article
- Ongoing impacts of childhood-onset glomerular diseases during young adulthood.Pediatric nephrology (Berlin, Germany) · 2024Article
- Management of hypertension in patients with cancer: challenges and considerations.Clinical kidney journal · 2023Review
- The Intersection of Prostate Cancer and Hypertension: a Call to Action.Current treatment options in oncology · 2023Review
- Antihypertensive effects of immunosuppressive therapy in autoimmune disease.Journal of human hypertension · 2023Article
- Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertension-Mechanisms and Mitigation.Hypertension (Dallas, Tex. : 1979) · 2023Review
- Epigenetic modifications and fetal programming: Molecular mechanisms to control hypertension inheritance.Biochemical pharmacology · 2023Review
- Normal ambulatory blood pressure in young adults with 21-hydroxylase enzyme deficiency undergoing glucocorticoid replacement therapy.Archives of endocrinology and metabolism · 2023Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucocorticoid-induced hypertension is a common clinical problem that is poorly understood, thus rendering treatment strategies sub-optimal. This form of hypertension has been commonly thought to be mediated by excess sodium and water reabsorption by the renal mineralocorticoid receptor. However, experimental and clinical data in both humans and animal models suggest important roles for the glucocorticoid receptor as well, in both the pathogenesis and maintenance of this hypertension. The glucocorticoid receptor is widely expressed in a number of organ systems relevant to blood pressure regulation, including the kidney, the brain and the vasculature. In vitro studies in isolated kidney tissues as well as in vascular smooth muscle and vascular endothelial cells have attempted to elucidate the molecular physiology of glucocorticoid-induced hypertension, but have generally been limited by the inability to study signaling pathways in an intact organism. More recently, the power of mouse genetics has been employed to examine the tissue-specific contributions of vascular and extra-vascular tissues to this form of hypertension. Here we review recent developments in our understanding of the pathogenesis of glucocorticoid-induced hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.